What is the net share impact of the Axsome Therapeutics COO’s recent Form 4 transactions?

The transaction summary shows 4,750 shares acquired through option exercises and 4,750 shares sold, resulting in net-sell activity of 4,750 shares. While direct common share holdings fell to zero, the insider continues to hold substantial stock options in the company.

Axsome COO exercises options, sells 4,750 shares

Axsome Therapeutics, Inc. Chief Operating Officer Mark L. Jacobson reported an exercise-and-sell transaction in company stock.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Axsome Therapeutics, Inc. Chief Operating Officer Mark L. Jacobson reported an exercise-and-sell transaction in company stock. He exercised stock options to acquire 4,750 shares of common stock at $12.95 per share, then sold the same 4,750 shares in open-market transactions at weighted average prices of about $227.94 and $228.18.

The footnotes state these options had been held for 7 years and were exercised before their 10-year expiration, and that the sales were made under a pre-approved Rule 10b5-1 plan, which has now been completed. Following the sales, he reports no directly held common shares but continues to hold 114,954 stock options expiring on March 19, 2029.

Insider Trade Summary 10b5-1

Exercise and Sale: 4,750 shares ($1.02M approx. pre-tax spread)

Exercise and Sale 6 txns

Insider Jacobson Mark L.

Role Chief Operating Officer

Sold 4,750 shs ($1.08M)

Approx. gross sale proceeds $1.08M

Approx. exercise cost $62K

Approx. pre-tax spread $1.02M

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	233	$0.00	$0.00
Exercise	Common Stock	233	$12.95	$3K
Sale	Common Stock	233	$228.18	$53K
Exercise	Stock Option (Right to Buy)	4,517	$0.00	$0.00
Exercise	Common Stock	4,517	$12.95	$58K
Sale	Common Stock	4,517	$227.94	$1.03M

Holdings After Transaction: Stock Option (Right to Buy) — 114,954 contracts (Direct); Common Stock — 0 shares (Direct)

Footnotes (5)

F1. Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options.
F2. Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.
F3. Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
F4. Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $225.12 and $231.97.
F5. Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $225.01 and $230.77.

Key Figures

Shares sold: 4,750 shares Weighted average sale prices: $227.94 and $228.18 per share Option exercise price: $12.95 per share +4 more

7 metrics

Shares sold 4,750 shares Common stock sold in open-market transactions

Weighted average sale prices $227.94 and $228.18 per share Open-market sale prices for common stock

Option exercise price $12.95 per share Conversion or exercise price for stock options

Options exercised 4,750 options Stock options converted into common shares

Remaining stock options 114,954 options Stock options held after transactions, expiring March 19, 2029

Option expiration date March 19, 2029 Final expiration for the reported stock option grant

Sale price ranges $225.01–$231.97 per share Ranges for series of open-market sale transactions

Key Terms

Rule 10b5-1 plan, stock options, open market transactions, weighted average sale price, +1 more

5 terms

Rule 10b5-1 plan financial

"Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

stock options financial

"Represents an exercise of stock options which were held for 7 years"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

open market transactions financial

"Represents the weighted average sale price of a series of open market transactions"

Open market transactions are the buying and selling of a company’s shares or other securities conducted on public exchanges or through the wider market rather than through private deals or negotiated placements. They matter to investors because these trades change supply and demand in real time—like shoppers affecting a store’s inventory—and so can move prices, signal management or investor sentiment, affect liquidity, and alter ownership stakes that influence future returns and risk.

weighted average sale price financial

"Represents the weighted average sale price of a series of open market transactions"

derivative exercise/conversion financial

"transaction_action": "derivative exercise/conversion""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Axsome Therapeutics (AXSM) report for Mark L. Jacobson?

Axsome Therapeutics reported that COO Mark L. Jacobson exercised options for 4,750 common shares at $12.95 per share and sold all 4,750 shares in open-market trades around $228 per share, according to the Form 4 filing and related footnotes.

Were the recent AXSM insider stock sales by the COO under a 10b5-1 plan?

Yes. The filing footnotes state the transactions were executed under a pre-approved Rule 10b5-1 trading plan. This type of plan pre-schedules trades, indicating the timing was planned rather than discretionary. The footnote also notes that this particular plan has now been completed.

How many Axsome Therapeutics (AXSM) shares did the COO sell and at what prices?

The COO sold 4,750 common shares of Axsome Therapeutics in open-market transactions. Weighted average sale prices were about $227.94 and $228.18 per share, with individual trades ranging roughly between $225.01 and $231.97, as detailed in the footnotes.

What stock options did the Axsome Therapeutics COO exercise in this Form 4 filing?

He exercised stock options covering 4,750 shares of common stock at a conversion or exercise price of $12.95 per share. The options were originally granted with a March 19, 2029 expiration date and had been held for approximately seven years before exercise, according to the footnotes.

Does the Axsome Therapeutics (AXSM) COO still hold shares after these transactions?

After the reported sales, the Form 4 shows zero directly held common shares for the COO. However, it lists 114,954 stock options remaining following the derivative transactions, with an expiration date of March 19, 2029, indicating he retains a significant derivative position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/05/2026 - 08:34 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jacobson Mark L.

(Last)

(First)

(Middle)

C/O AXSOME THERAPEUTICS, INC.

ONE WORLD TRADE CENTER, 29TH FLOOR

(Street)

NEW YORK

10007

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Axsome Therapeutics, Inc. [ AXSM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/04/2026		M⁽¹⁾⁽²⁾		4,517	A	$12.95	4,517	D
Common Stock	05/04/2026		S⁽²⁾⁽³⁾		4,517	D	$227.94⁽⁴⁾	0	D
Common Stock	05/05/2026		M⁽¹⁾⁽²⁾		233	A	$12.95	233	D
Common Stock	05/05/2026		S⁽²⁾⁽³⁾		233	D	$228.18⁽⁵⁾	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$12.95	05/04/2026		M⁽¹⁾⁽²⁾			4,517	03/19/2020	03/19/2029	Common Stock	4,517	$0.00	115,187	D
Stock Option (Right to Buy)	$12.95	05/05/2026		M⁽¹⁾⁽²⁾			233	03/19/2020	03/19/2029	Common Stock	233	$0.00	114,954	D

Explanation of Responses:

1. Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options.

2. Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.

3. Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.

4. Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $225.12 and $231.97.

5. Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $225.01 and $230.77.

	/s/ Mark Jacobson	05/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR